Anthony P. Shuber

Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. The Company pioneered the Clinical Intervention Determining Diagnostic (CIDD) and Multi-Analyte Diagnostic Readout (MADR) approaches to cancer management, leveraging its portfolio of patented biomarkers and clinical algorithms. Based on these approaches, the Company is building a unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence. Predictive Biosciences' first tests are targeted toward the growing bladder cancer and prostate cancer survivor populations and the large number of individuals undergoing clinical workups for these malignancies. Predictive Biosciences' corporate headquarters and innovation center is located in Lexington, Massachusetts. The Company's commercial division, OncoDiagnostic Laboratory (ODL), is located in Cleveland, Ohio. ODL is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians. Founded in 2006, Predictive Biosciences is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates.

Genzyme Genetics, Inc. provides laboratory testing and diagnostic services specifically for reproductive and oncology tests. It provides tests for cystic fibrosis carriers and cancers. The company is headquartered in Westborough, MA.

Part of Laboratory Corp. of America Holdings, Integrated Genetics, Inc. is a pharmaceutical preparations company. The company is based in Framingham, MA. The company was founded by Robert J. Carpenter.

NABsys, Inc. developed DNA analysis sequencing platform. Its platform used solid-state nanodetectors to analyze single DNA molecules, revealing both location and identity of DNA sequences over long distances. The firm system was designed to set new standards for accuracy, speed and scalability, offering compelling advantages for the analysis of genome structural variation, genome mapping, and both targeted and whole genome sequencing. The company was founded by Xinsheng Sean Ling, Leon N. Cooper and Barrett Bready in 2004 and was headquartered in Providence, RI.

Ignyta, Inc. operates as a medicine biotechnology company. The firm engages in the discovering, acquiring, developing and commercializing targeted new drugs for cancer patients. The company was founded by Jonathan E. Lim on September 13, 2011 and is headquartered in South San Francisco, CA.

Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA.